Skip to main content

Search

Reset all filters
22 Result(s)
Sort by

Our Vision

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
A Clear Vision

A Clear Vision

Take a tour of our journey into Retinal Health through this interactive infographic or descriptive audio recording, and learn how we aim to preserve or restore vision in people with retinal diseases.
Retinal health

Retinal health

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in Retinal Health.
Oncology

Oncology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Our Partnering Culture

Our Partnering Culture

We embrace the power of partnerships and alliances to find even more breakthrough therapies that change lives.
BI Access to Healthcare Strategy_Availability

BI Access to Healthcare Strategy_Availability

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Congress Patient Benefit

Congress Patient Benefit

The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Championing novel science

Championing novel science

Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Innovation Prize Winners

Innovation Prize Winners

Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
Mechanistic Modeling in Biotherapeutic Drug Development

Mechanistic Modeling in Biotherapeutic Drug Development

Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.